Your session is about to expire
← Back to Search
Dexamethasone + rhCG for Polycystic Ovary Syndrome (CBS001 Trial)
N/A
Waitlist Available
Led By Christine Burt Solorzano, MD
Research Sponsored by University of Virginia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Girls age 7-18 years
Normal weight (BMI 5-85%-ile for age) or overweight (>85%-ile)
Must not have
Previous diagnosis of diabetes, fasting glucose ≥126 mg/dL, or a hemoglobin A1c >6.5%
Inability to comprehend what will be done during the study or why it will be done
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group
Approved for 60 Other Conditions
Summary
This trial is studying how the ovaries contribute to the production of male hormones in the body during different stages of puberty.
Who is the study for?
This trial is for girls aged 7-18 who may have signs of excess male hormones, like facial hair or irregular periods. They should be normal weight or overweight but not obese and must have normal lab results except for minor variations due to obesity. Girls with certain health conditions or on other research protocols are excluded.
What is being tested?
The study investigates how the ovaries contribute to producing male hormones in adolescent girls at different puberty stages, using medications Dexamethasone and rhCG. This could help understand why some females develop high levels of these hormones.
What are the potential side effects?
Potential side effects from Dexamethasone include increased appetite, mood changes, difficulty sleeping, and higher risk of infections. The use of rhCG might cause pain at the injection site, headaches, fatigue, and hormonal changes.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am a girl aged between 7 and 18.
Select...
My BMI is within the normal or overweight range for my age.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have diabetes or my blood sugar/A1c levels are high.
Select...
I understand what the study involves and why it's being done.
Select...
I have a history of congenital adrenal hyperplasia or my 17-hydroxyprogesterone levels are above 300 ng/dL.
Select...
My BMI is below the 5th percentile for my age.
Select...
My thyroid hormone levels are not normal for my age.
Select...
I am obese due to a genetic condition like Prader-Willi syndrome.
Select...
My morning cortisol is low or I have had Cushing syndrome or adrenal issues.
Select...
I am not a boy.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Approved for 60 Other Conditions
This treatment demonstrated efficacy for 60 other conditions.
Trial Design
1Treatment groups
Experimental Treatment
Group I: dexamethasone, rhCG (Ovidrel)Experimental Treatment2 Interventions
rhCG (Ovidrel) administered 25 mcg IV; dexamethasone administered 1 mg PO
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dexamethasone
FDA approved
Find a Location
Who is running the clinical trial?
University of VirginiaLead Sponsor
785 Previous Clinical Trials
1,316,366 Total Patients Enrolled
University of California, San DiegoOTHER
1,189 Previous Clinical Trials
1,587,661 Total Patients Enrolled
Christine Burt Solorzano, MDPrincipal Investigator - University of Virginia Center for Research in Reproduction
UVA Child Development & Rehabilitation Center, University of Virginia Medical Center
University Of Virginia School Of Medicine (Medical School)
Children'S Hosp Of L A (Residency)
7 Previous Clinical Trials
215 Total Patients Enrolled